CGS International EBITDA per Share
The EBITDA per Share of CGS International (CGSI) as of Oct 31, 2026 is -0.63 USD.
Get this data via API
Financial Data API
EBITDA per Share
-0.63USD
YoY
21,976.76%
Last updated:
EBITDA per Share of CGS International is 2022 -0.63 USD. EBITDA per Share of CGS International was 2021 -0.00 USD. It decreases by 21,976.76% lower compared to the previous year.
The CGS International EBITDA per Share history
3 Years
10 Years
25 Years
Max
EBITDA per Share
Date
EBITDA per Share
Jan 1, 2015
-0.13 USD
Jan 1, 2016
-0.16 USD
Jan 1, 2017
-0.14 USD
Jan 1, 2018
-0.00 USD
Jan 1, 2019
-0.18 USD
Jan 1, 2020
-0.02 USD
Jan 1, 2021
-0.00 USD
Jan 1, 2022
-0.63 USD
| YEAR | EBITDA per Share | YoY |
|---|---|---|
| -0.63USD | +21,976.76% | |
| -0.00USD | -87.41% | |
| -0.02USD | -87.26% | |
| -0.18USD | +10,938.88% | |
| -0.00USD | -98.87% | |
| -0.14USD | -10.78% | |
| -0.16USD | +22.06% | |
| -0.13USD | -39.43% | |
| -0.22USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
CGS International Stock analysis
What does CGS International do? CGS International, Inc. intends to provide TVs streaming advertisements for customers lining up outside nightclubs. The company also operates WAM, a sole-proprietorship focused on commercial agriproducts. WAM produces GENESIS 89 and GENESIS 89 Gold, formulated using minerals extracted from deep-ocean deposits combined with organic ingredients. GENESIS 89 contains over 80 trace minerals and serves as a soil amendment or foliar spray, while GENESIS 89 Gold is specifically designed for the cannabis industry and shipped as a concentrate to commercial growers.
The primary buyers of GENESIS 89 and GENESIS 89 Gold are commercial growers in the cannabis industry, particularly for GENESIS 89 Gold. GENESIS 89 targets agricultural applications through soil amendment and foliar spray uses. The company's revenue streams come from the sale of these agriproducts, with GENESIS 89 Gold being tailored for cannabis growers who require specialized organic growth supplements.
WAM, operating under CGS International, markets GENESIS 89 and GENESIS 89 Gold as premium organic growth supplements. The products are distributed as concentrates to commercial growers, emphasizing their natural mineral extraction process and organic formulation. The cannabis industry segment represents a key market for GENESIS 89 Gold, while broader agricultural sectors use GENESIS 89 for soil and plant health applications. CGS International is one of the most popular companies on Eulerpool.
Frequently Asked Questions about CGS International stock
EBITDA per Share of CGS International is -0.63 USD in 2022.
On Eulerpool you can find the complete historical development of EBITDA per Share CGS International since 2006 – with annual values, charts, and detailed analysis.
EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — CGS International
All Key Metrics — CGS International
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth